Dublin, Dec. 22, 2022 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global atrial fibrillation treatment market size reached US$ 6.3 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 12.4 Billion by 2027, exhibiting a CAGR of 11.95% during 2021-2027.
| Report Attribute | Details |
| No. of Pages | 144 |
| Forecast Period | 2021 - 2027 |
| Estimated Market Value (USD) in 2021 | $6.3 Billion |
| Forecasted Market Value (USD) by 2027 | $12.4 Billion |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | Global |
Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Atrial fibrillation (AFib) refers to a cardiac condition with irregular and rapid heart rate that increases the risks of stroke, heart failure and other heart-related complications. In this condition, the upper (atrial) chambers beat irregularly and out of coordination with the lower (ventricle) chambers of the heart, thereby causing heart palpitations, shortness of breath and fatigue.
It can also lead to the development of blood clots that may disrupt the blood flow to other organs. The main types of AFib include paroxysmal, persistent, long-term persistent, and permanent AFib that can be treated with medications and other interventions to adjust the heart's electrical impulses.
The rising prevalence of cardiovascular diseases (CVDs) is one of the key factors driving the growth of the market. Such disorders are highly prevalent among the geriatric population and individuals suffering from other ailments, such as diabetes, hypertension and cardiovascular diseases (CVDs). This, along with the steadily increasing geriatric population across the globe, is providing a boost to the market growth.
Furthermore, the increasing preference for minimally invasive (MI) surgical procedures is also creating a positive impact on the demand for miniaturized surgical devices, implant surgeries and remote nursing.
Additionally, various technological advancements, such as the development of catheter ablation devices to remove damaged heart tissues and innovative mapping and recording systems, is acting as another growth-inducing factor. Other factors, including improvements in the healthcare infrastructure and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Atricure Inc., Biotronik, Boston Scientific Corporation, Cardiofocus Inc., Hansen Medical Inc. (Auris Health), Johnson & Johnson, Siemens Healthineers, Stereotaxis Inc., etc.
Key Questions Answered in This Report:
- How has the global atrial fibrillation treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global atrial fibrillation treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the disorder type?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the end-user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global atrial fibrillation treatment market and who are the key players?
- What is the degree of competition in the industry?
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Atrial Fibrillation Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Disorder Type
6.1 Paroxysmal Atrial Fibrillation
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Persistent Atrial Fibrillation
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Permanent Atrial Fibrillation
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Treatment Type
7.1 Medical Procedures
7.1.1 Market Trends
7.1.2 Surgical Procedures
7.1.2.1 Maze Surgery
7.1.2.2 Catheter Ablation
7.1.3 Non-Surgical Devices
7.1.3.1 Electric Cardioversion
7.1.3.2 Diagnostic Catheters
7.1.3.3 Mapping and Recording Systems
7.1.3.4 Cardiac Monitors
7.1.3.5 Access Devices
7.1.3.6 Left Atrial Appendage and Closure Devices
7.1.3.7 Intracardiac Echocardiography (ICE) Systems
7.1.4 Market Forecast
7.2 Medications
7.2.1 Market Trends
7.2.2 Drug Class
7.2.2.1 Anticoagulants
7.2.2.2 Anti-Arrhythmics
7.2.3 Market Forecast
8 Market Breakup by End-User
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Cardiac Labs
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Ambulatory Surgical Centers
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
10 SWOT Analysis
11 Value Chain Analysis
12 Porters Five Forces Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Abbott Laboratories
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 Atricure Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 Biotronik
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.4 Boston Scientific Corporation
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 SWOT Analysis
13.3.5 Cardiofocus Inc.
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.6 Hansen Medical Inc. (Auris Health)
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.7 Johnson & Johnson
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 Siemens Healthineers
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.9 Stereotaxis Inc.
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.9.4 SWOT Analysis
For more information about this report visit https://www.researchandmarkets.com/r/oa5hzh
Attachment
